• -8%-8% Therapeutic Targeting of RAS Mutant Cancers

    Therapeutic Targeting of RAS Mutant Cancers

    Kendra Paskvan, Shumei Kato

    Part of Elements in Molecular Oncology

    The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS […]

     Original price was: 22,00€.Η τρέχουσα τιμή είναι: 20,00€.(Περιλαμβάνεται ΦΠΑ 6%)
    Προσθήκη στο καλάθι